The Taiwanese Energenesis Biomedical Co., Ltd. (TWSE: 6657) signed a Memorandum of Understanding (MOU) with Healiva SA, solidifying their collaboration in the development and commercialization of ENERGI-F703, a topical gel for the treatment of diabetic foot ulcers, in Switzerland and Europe.
The signed MOU between the two companies outlines the key objectives of the clinical collaboration between Energenesis and Healiva in Europe. It aims to facilitate the planning and coordination of future clinical trials in Switzerland and EU countries, including a sequential clinical trial involving Healiva's own product, in conjunction with the ENERGI-F703 gel.
To expedite the global market entry of the ENERGI-F703 gel, Energenesis is currently conducting a Phase III clinical trial in the United States and has also planned a Phase III clinical trial in Europe. Additionally, the MOU paves the way for the second Phase III clinical trial of the ENERGI-F703 gel, ensuring compliance with FDA regulations in the United States and EMA regulations in Europe.
Energenesis and Healiva anticipate that their collaboration in the development of wound care products will contribute to the integration of comprehensive treatments for chronic wound care, delivering enhanced medical care to patients, and accelerating the global expansion of their product offerings.